French drugmaker Sanofi Aventis SA said on Sunday it was in discussions with US bid target Genzyme Corp over ways to value a key Genzyme drug, but there was no guarantee an agreement would be reached.
Sanofi has offered to acquire Genzyme, a maker of drugs for rare diseases, for USD 18.5 billion, or USD 69 a share -- a figure Genzyme says is too low.Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
